A Single Center, Double-Blind, Randomized, Double Dummy, Placebo-Controlled, Three-Period Crossover Study to Assess the Effects of a mGluR2/3 Positive Allosteric Modulator [AZD8529] Upon Ketamine-Induced Cortical Stimulation and Impairment of Working-Memory Related Activation of the Prefrontal Cortex.
Phase of Trial: Phase 0
Latest Information Update: 18 Jun 2015
At a glance
- Drugs AZD 8529 (Primary)
- Indications Schizophrenia
- Focus Pharmacodynamics
- 18 Jun 2015 Results presented at the 12th World Congress of Biological Psychiatry.
- 03 May 2011 Actual end date (1 Apr 2011) added as reported by ClinicalTrials.gov.
- 03 May 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.